Kelly E. McCann, MD, PhD

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

Kelly E. McCann, MD, PhD, discusses findings from the VIKTORIA-1 trial of gedatolisib-based regimens in hormone receptor–positive advanced breast cancer.

Kelly McCann, MD, PhD, discusses the relevance of patient preferences during treatment decision-making for patients with HER2-positive breast cancer.

Panelists discuss how the field has made exciting strides, with oral selective estrogen receptor degraders (SERDs) likely moving into early-stage disease and the need for alternative antibody-drug conjugate (ADC) payloads beyond topoisomerase I inhibitors to overcome resistance mechanisms.

Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

Panelists discuss how they approach sequencing decisions for patients with hormone receptor–positive, HER2- low/ultralow disease, emphasizing selective use of trastuzumab deruxtecan in first-line chemotherapy settings while considering quality-of-life factors.

Panelists discuss how subgroup analyses from DESTINY-Breast06 show trastuzumab deruxtecan benefits across different mutation groups, with particularly strong responses in patients with BRCA1/2-mutated disease due to the topoisomerase I inhibitor payload.

Panelists discuss how treatment options for HER2-low and HER2-ultralow metastatic breast cancer include trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, with sequencing becoming a key consideration.

Panelists discuss how to manage toxicities associated with datopotamab deruxtecan, particularly ocular toxicity and stomatitis, using prophylactic measures such as steroid mouthwash and eye drops.

Panelists discuss how datopotamab deruxtecan from the TROPHY-PD-01 trial compares with sacituzumab govitecan, highlighting different toxicity profiles and the challenge of sequencing multiple antibody-drug conjugates (ADCs) with the same TROP2 payload.

Panelists discuss how the TROPiCS-02 trial established sacituzumab govitecan for hormone receptor–positive, HER2-negative metastatic breast cancer and how it influences sequencing decisions with other antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan.

Panelists discuss how they decide when to transition from endocrine-based therapies to antibody-drug conjugates, considering factors such as endocrine sensitivity, disease burden, and pace of progression.

Panelists discuss how to approach decision-making among PI3K/AKT pathway inhibitors (capivasertib, alpelisib, everolimus) based on mutation status, toxicity profiles, and dosing schedules in the second-line setting.

Kelly McCann, MD, PhD, discusses the need to reach consensus on the potential role of vepdegestrant for ER-positive, HER2-negative advanced breast cancer.

Panelists discuss how upcoming oral selective estrogen receptor degraders (SERDs; eg, camasertinib, imlunestrant, and giredestrant) are showing efficacy primarily in populations with ESR1 mutations and are all well-tolerated oral agents that will likely receive approvals.

Panelists discuss how elacestrant from the EMERALD trial is being incorporated into practice based on ESR1 mutation status and duration of prior CDK4/6 inhibitor therapy, with combination approaches being explored in the ELEVATE trial.

Panelists discuss how the SERENA-6 trial design uses circulating tumor DNA (ctDNA) monitoring to detect ESR1 mutations and switch patients from aromatase inhibitors to oral selective estrogen receptor degraders (SERDs) such as camasertinib while continuing CDK4/6 inhibitors.

Panelists discuss how they will review the latest updates in hormone receptor–positive, HER2-negative, and HER2-low metastatic breast cancer, focusing on oral selective estrogen receptor degraders (SERDs), targeted therapies, and antibody-drug conjugates presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Panelists discuss how emerging developments in HER2-positive (HER2+) breast cancer treatment, including novel antibody-drug conjugates, bispecific antibodies, and cytotoxic-sparing regimens for hormone receptor+ (HR+)/HER2+ disease, are creating exciting new options for patients.

Panelists discuss how they approach treatment beyond third-line therapy for HER2-positive (HER2+) metastatic breast cancer, considering factors such as prior therapies, residual toxicities, and patient preferences when selecting from multiple options.

Panelists discuss how they manage adverse effects of tucatinib-based therapy, particularly focusing on diarrhea and palmar-plantar erythrodysesthesia from capecitabine, with practical dosing strategies to improve tolerability.

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Panelists discuss how treatment decisions in later-line settings should incorporate clinical trials, patient preferences regarding quality of life, medication scheduling, financial considerations, and previous adverse effect experiences, while also addressing special considerations for brain metastases.